Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

Real-world data confirm PSA cutoffs for prognosis in patients treated for metastatic hormone-sensitive prostate cancer.

The immunotherapy CAN-2409 plus radiation therapy may fill an unmet treatment need for patients with localized intermediate- to high-risk prostate cancer.

Health care data breaches that compromised protected health information more than doubled from 2010 to 2024 in the US, data suggest.

Chronic kidney disease (CKD) and hypertension are common health problems among childhood cancer survivors with potentially life-threatening sequelae.